Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Dec;37(12):970-3.

[ADOC regimen for unresectable advanced thymic cancer]

[Article in Japanese]
T Koizumi  1 , Y Takabayashi, S Yamagishi, K Tsushima, A Takamizawa, S Takashi, A Tsukadaira, T Masubuchi, H Yamamoto, T Kaneki, S Yamaguchi, T Hachiya, M Hayasaka, K Fujimoto, K Kubo
Affiliations
  • PMID: 10707536
Clinical Trial

[ADOC regimen for unresectable advanced thymic cancer]

[Article in Japanese]
T Koizumi et al. Nihon Kokyuki Gakkai Zasshi. 1999 Dec.

Abstract

Between 1996 and 1998, we treated 6 patients with unresectable and advanced thymic cancer (stages IVa and IVb). All received 50 mg/m2 of cisplatin and 40 mg/m2 of doxorubicin intravenously (i.v.) on day 1,0.6 mg/m2 of vincristine i.v. on day 3, and 700 mg/m2 of cyclophosphamide i.v. on day 4; ADOC regimen, respectively at 3-4 week intervals. Four patients obtained a partial response (PR) after ADOC chemotherapy and the overall clinical response rate was 67%. No life-threatening side effects were noted. In 2 patients, cisplatin plus VP-16 chemotherapy failed to demonstrate any benefits prior to the ADOC regimen. Radiotherapy was initiated after the achievement of PR in the other 2 patients. ADOC chemotherapy appears to be an effective treatment for thymic cancer.

PubMed Disclaimer

Supplementary concepts